- Home
- SRRK vs BFH Comparison
SRRK vs BFH Comparison
Compare SRRK & BFH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRRK
- BFH
- Stock Information
- Founded
- SRRK 2012
- BFH 1996
- Country
- SRRK United States
- BFH United States
- Employees
- SRRK N/A
- BFH N/A
- Industry
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- BFH Business Services
- Sector
- SRRK Health Care
- BFH Consumer Discretionary
- Exchange
- SRRK Nasdaq
- BFH Nasdaq
- Market Cap
- SRRK 2.8B
- BFH 2.3B
- IPO Year
- SRRK 2018
- BFH N/A
- Fundamental
- Price
- SRRK $26.49
- BFH $58.51
- Analyst Decision
- SRRK Strong Buy
- BFH Hold
- Analyst Count
- SRRK 7
- BFH 19
- Target Price
- SRRK $34.00
- BFH $48.63
- AVG Volume (30 Days)
- SRRK 984.5K
- BFH 800.2K
- Earning Date
- SRRK 11-12-2024
- BFH 10-24-2024
- Dividend Yield
- SRRK N/A
- BFH 1.44%
- EPS Growth
- SRRK N/A
- BFH N/A
- EPS
- SRRK N/A
- BFH 6.25
- Revenue
- SRRK N/A
- BFH $2,467,000,000.00
- Revenue This Year
- SRRK N/A
- BFH N/A
- Revenue Next Year
- SRRK N/A
- BFH $1.04
- P/E Ratio
- SRRK N/A
- BFH $9.27
- Revenue Growth
- SRRK N/A
- BFH N/A
- 52 Week Low
- SRRK $6.76
- BFH $26.58
- 52 Week High
- SRRK $35.38
- BFH $63.01
- Technical
- Relative Strength Index (RSI)
- SRRK 50.87
- BFH 60.79
- Support Level
- SRRK $25.86
- BFH $56.28
- Resistance Level
- SRRK $28.11
- BFH $61.67
- Average True Range (ATR)
- SRRK 1.68
- BFH 2.17
- MACD
- SRRK -0.92
- BFH 0.37
- Stochastic Oscillator
- SRRK 11.71
- BFH 66.57
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
About BFH Bread Financial Holdings Inc.
Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains minority interest in its recently spun-off LoyaltyOne division, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.